Nuon Therapeutics, Inc. is a clinical stage biopharmaceutical company developing medicines to treat autoimmune disease and inflammation.
The company's lead compound is the oral drug tranilast, which is being evaluated in preclinical trials for multiple sclerosis and in clinical trials for rheumatoid arthritis.
Nuon Therapeutics, Inc. is committed to advancing novel therapies through clinical development in well-designed, and cost-effective trials.
